Article: article from journal or magazin.
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Traitement du diabète de type 2: qu'attendre des analogues du GLP-1 et inhibiteurs de la DPP-4? [What can be expected from the GLP-1 agonists and DPP-4 inhibitors in the treatment of type 2 diabetes?]
Revue Médicale Suisse
Egli, M Ruiz, J English Abstract Review Switzerland Revue medicale suisse Rev Med Suisse. 2007 Jun 6;3(114):1449-50, 1453-5. --- Old month value: Jun 6 --- Old uritopublisher value: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17639666
The GLP-1 agonists and DPP-4 inhibitors are two novel drug classes in the treatment of type 2 diabetes. They increase insulin secretion and inhibit glucagon secretion without risk of hypoglycaemia. A decrease of glycated haemoglobin of about 1% can be expected with their use as monotherapy and as add-on therapy to the usual oral antidiabetics. In addition, GLP-1 agonists induce weight reduction at the price of gastro-intestinal side-effects and the need for subcutaneous administration. DPP-4 inhibitors can be taken orally, are well-tolerated, but weight-neutral. In the absence of relevant clinical studies, their long-term efficacy is currently unknown, as well as the clinical impact of other promising effects like beta-cell preservation.
Antigens, CD26/antagonists & inhibitors Diabetes Mellitus, Type 2/*drug therapy Glucagon-Like Peptide 1/analogs & derivatives Humans Hypoglycemic Agents/pharmacology/*therapeutic use
Last modification date